Keros Therapeutics Inc
KROS
Company Profile
Business description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Contact
1050 Waltham Street
Suite 302
LexingtonMA02421
USAT: +1 617 314-6297
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,211.00 | 48.20 | -0.52% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,613.19 | 354.90 | -1.27% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,153.70 | 221.90 | -0.42% |
| NZX 50 Index | 13,389.90 | 41.29 | 0.31% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,912.60 | 42.50 | -0.47% |
| SSE Composite Index | 4,113.95 | 44.04 | -1.06% |